Astellas Pharma (OTCMKTS:ALPMY – Get Free Report) is anticipated to announce its results after the market closes on Wednesday, August 5th. Analysts expect the company to post earnings of $0.3336 per share and revenue of $3.4489 billion for the quarter.
Astellas Pharma Trading Down 0.4%
Shares of OTCMKTS ALPMY opened at $13.67 on Tuesday. The firm’s 50 day moving average price is $13.41 and its 200-day moving average price is $14.63. Astellas Pharma has a 52-week low of $10.03 and a 52-week high of $17.35. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.90 and a current ratio of 1.17. The company has a market cap of $24.74 billion, a PE ratio of 12.73 and a beta of 0.08.
Wall Street Analysts Forecast Growth
Separately, Zacks Research lowered shares of Astellas Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 22nd. One investment analyst has rated the stock with a Strong Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold”.
About Astellas Pharma
Astellas Pharma Inc is a Tokyo-based, global pharmaceutical company traded in the United States as an American Depositary Receipt on the OTC Markets under the symbol ALPMY. The company focuses on discovering, developing and marketing prescription medicines in key therapeutic areas, including oncology, urology, immunology, neuroscience and cardiovascular/metabolic diseases. Astellas seeks to bring innovative treatments to market by combining internal research capabilities with external partnerships and collaborative agreements around the world.
Core products in Astellas’ portfolio include the immunosuppressant Prograf (tacrolimus), the overactive bladder treatments Vesicare (solifenacin) and Myrbetriq (mirabegron), and the prostate cancer therapy Xtandi (enzalutamide).
Read More
- Five stocks we like better than Astellas Pharma
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Astellas Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astellas Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
